KANSAS CITY, Kan., March 21, 2016 Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced the Food and Drug Administration’s Center for Veterinary Medicine (CVM) approved GALLIPRANT^® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs. Galliprant is expected to be available to veterinarians in fall 2016.